Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial
- PMID: 37640861
- PMCID: PMC10579092
- DOI: 10.1038/s41591-023-02532-z
Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial
Abstract
Measurement of natriuresis has been suggested as a reliable, easily obtainable biomarker for assessment of the response to diuretic treatment in patients with acute heart failure (AHF). Here, to assess whether natriuresis-guided diuretic therapy in patients with AHF improves natriuresis and clinical outcomes, we conducted the pragmatic, open-label Pragmatic Urinary Sodium-based algoritHm in Acute Heart Failure trial, in which 310 patients (45% female) with AHF requiring treatment with intravenous loop diuretics were randomly assigned to natriuresis-guided therapy or standard of care (SOC). In the natriuresis-guided arm, natriuresis was determined at set timepoints, prompting treatment intensification if spot urinary sodium levels were <70 mmol l-1. The dual primary endpoints were 24 h urinary sodium excretion and a combined endpoint of time to all-cause mortality or adjudicated heart failure rehospitalization at 180 days. The first primary endpoint was met, as natriuresis in the natriuresis-guided and SOC arms was 409 ± 178 mmol arm versus 345 ± 202 mmol, respectively (P = 0.0061). However, there were no significant differences between the two arms for the combined endpoint of time to all-cause mortality or first heart failure rehospitalization, which occurred in 46 (31%) and 50 (31%) of patients in the natriuresis-guided and SOC arms, respectively (hazard ratio 0.92 [95% confidence interval 0.62-1.38], P = 0.6980). These findings suggest that natriuresis-guided therapy could be a first step towards personalized treatment of AHF. ClinicalTrials.gov registration: NCT04606927 .
© 2023. The Author(s).
Conflict of interest statement
J.M.t.M. is supported by a Dekker grant of the Dutch Heart Foundation (2020T012) for this study. J.M.t.M. declares speaker fees to her institution from Boehringer Ingelheim and Novartis. P.v.d.M. declares speaker and consultancy fees to his institution from Vifor Pharma, Novo Nordisk, Pfizer, AstraZeneca, Ionis and Pharma Nord. J.E.C. declares speaker fees from Novartis, and has received fees from Cardiolysis for participation on a DSMB or advisory board. A.A.V. has received research support and/or has been a consultant for AnaCardio, Bayer, BMI, Boehringer Ingelheim, Corteria, Cytokinetics, Eli Lily, Merck, Novartis, Novo Nordisk and Roche Diagnostics. K.D. declares speaker and consultancy fees to his institution from Boehringer Ingelheim, AstraZeneca, Abbott, FIRE1 and EchoSense. The other authors declare no competing interests.
Figures
Similar articles
-
Natriuresis-guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial.Eur J Heart Fail. 2022 Feb;24(2):385-392. doi: 10.1002/ejhf.2385. Epub 2022 Jan 6. Eur J Heart Fail. 2022. PMID: 34791756 Free PMC article. Clinical Trial.
-
Renal function and natriuresis-guided diuretic therapy - a pre-specified analysis from the PUSH-AHF trial.Eur J Heart Fail. 2024 Jun;26(6):1347-1357. doi: 10.1002/ejhf.3228. Epub 2024 May 12. Eur J Heart Fail. 2024. PMID: 38734982 Clinical Trial.
-
Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance.Eur J Heart Fail. 2019 Nov;21(11):1415-1422. doi: 10.1002/ejhf.1478. Epub 2019 May 9. Eur J Heart Fail. 2019. PMID: 31074184 Clinical Trial.
-
A review regarding the article 'Basal natriuresis as a predictor of diuretic resistance and clinical evolution in acute heart failure'.Curr Probl Cardiol. 2024 Aug;49(8):102688. doi: 10.1016/j.cpcardiol.2024.102688. Epub 2024 May 29. Curr Probl Cardiol. 2024. PMID: 38821235 Review.
-
Diuretic Resistance in Heart Failure.Curr Heart Fail Rep. 2019 Apr;16(2):57-66. doi: 10.1007/s11897-019-0424-1. Curr Heart Fail Rep. 2019. PMID: 30762178 Free PMC article. Review.
Cited by
-
Advances in Clinical Cardiology 2023: A Summary of Key Clinical Trials.Adv Ther. 2024 Jul;41(7):2606-2634. doi: 10.1007/s12325-024-02877-y. Epub 2024 May 14. Adv Ther. 2024. PMID: 38743242 Free PMC article. Review.
-
The Changing Role of Loop Diuretics in Heart Failure Management across the Last Century.J Clin Med. 2024 Mar 14;13(6):1674. doi: 10.3390/jcm13061674. J Clin Med. 2024. PMID: 38541899 Free PMC article. Review.
-
Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF.Circ Heart Fail. 2024 Mar;17(3):e011246. doi: 10.1161/CIRCHEARTFAILURE.123.011246. Epub 2024 Mar 4. Circ Heart Fail. 2024. PMID: 38436075 Clinical Trial.
-
Prognostic Impact of Induced Natriuresis in Acute Decompensated Heart Failure and Its Association with Intraabdominal Pressure and Other Congestion Markers: A Multimodal Approach to Congestion Assessment.J Clin Med. 2024 Feb 12;13(4):1053. doi: 10.3390/jcm13041053. J Clin Med. 2024. PMID: 38398366 Free PMC article.
-
Decongestion in Acute Heart Failure-Time to Rethink and Standardize Current Clinical Practice?J Clin Med. 2024 Jan 5;13(2):311. doi: 10.3390/jcm13020311. J Clin Med. 2024. PMID: 38256444 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous